OnPoint Analytics

Biosimilars Tracker Last Updated: June 14, 2021

Reference Biologic Drug: EPOGEN/PROCRIT (epoetin alfa, 1989)

# of Biosimilars Approved:
1
Biosimilars Status
% Commercial Lives Covered
Litigation
Biosimilar Names
Approval Dates
On Market
Biologic
Biosimilars
Patent
Antitrust
53%
RETACRIT
5/15/2018
Y
96%
Y

Reference Biologic Drug: NEUPOGEN (filgrastim, 1991)

# of Biosimilars Approved:
2
Biosimilars Status
% Commercial Lives Covered
Litigation
Biosimilar Names
Approval Dates
On Market
Biologic
Biosimilars
Patent
Antitrust
49%
ZARXIO
3/6/2015
Y
82%
Y
NIVESTYM
7/20/2018
Y
87%
Y

Reference Biologic Drug: RITUXAN (rituximab, 1997)

# of Biosimilars Approved:
3
Biosimilars Status
% Commercial Lives Covered
Litigation
Biosimilar Names
Approval Dates
On Market
Biologic
Biosimilars
Patent
Antitrust
67%
TRUXIMA
11/28/2018
Y
46%
Y
(settled)
RUXIENCE
7/23/2019
Y
54%
N
RIABNI
12/17/2020
Y
52%
N

Reference Biologic Drug: ENBREL (etanercept, 1998)

# of Biosimilars Approved:
2
Biosimilars Status
% Commercial Lives Covered
Litigation
Biosimilar Names
Approval Dates
On Market
Biologic
Biosimilars
Patent
Antitrust
100%
ERELZI
8/30/2016
N
24%
Y
ETICOVO
4/25/2019
N
23%
Y

Reference Biologic Drug: HERCEPTIN (trastuzumab, 1998)

# of Biosimilars Approved:
5
Biosimilars Status
% Commercial Lives Covered
Litigation
Biosimilar Names
Approval Dates
On Market
Biologic
Biosimilars
Patent
Antitrust
65%
OGIVRI
12/1/2017
Y
45%
N
HERZUMA
12/14/2018
Y
38%
Y
(settled)
ONTRUZANT
1/18/2019
Y
54%
Y
(settled)
TRAZIMERA
3/11/2019
Y
64%
Y
(settled)
KANJINTI
6/13/2019
Y
78%
Y

Reference Biologic Drug: REMICADE (infliximab, 1998)

# of Biosimilars Approved:
4
Biosimilars Status
% Commercial Lives Covered
Litigation
Biosimilar Names
Approval Dates
On Market
Biologic
Biosimilars
Patent
Antitrust
75%
Y
INFLECTRA
4/5/2016
Y
63%
Y
RENFLEXIS
4/21/2017
Y
60%
Y
IXIFI
12/13/2017
N
N
AVSOLA
12/6/2019
Y
57%
N

Reference Biologic Drug: HUMIRA (adalizumab, 2002)

# of Biosimilars Approved:
6
Biosimilars Status
% Commercial Lives Covered
Litigation
Biosimilar Names
Approval Dates
On Market
Biologic
Biosimilars
Patent
Antitrust
100%
Y
AMJEVITA
9/23/2016
N
Y
(settled)
CYLTEZO
8/25/2017
N
Y
(settled)
HYRIMOZ
10/30/2018
N
Y
(settled)
HADLIMA
7/23/2019
N
N
ABRILADA
11/15/2019
N
N
HULIO
7/6/2020
N
Y
(settled)

Reference Biologic Drug: NEULASTA (pegfilgrastim, 2002)

# of Biosimilars Approved:
4
Biosimilars Status
% Commercial Lives Covered
Litigation
Biosimilar Names
Approval Dates
On Market
Biologic
Biosimilars
Patent
Antitrust
64%
FULPHILA
6/4/2018
Y
68%
Y
UDENYCA
11/2/2018
Y
55%
Y
ZIEXTENZO
11/4/2019
Y
94%
Y
NYVEPRIA
6/10/2020
Y
80%
Y

Reference Biologic Drug: AVASTIN (bevacizumab, 2004)

# of Biosimilars Approved:
2
Biosimilars Status
% Commercial Lives Covered
Litigation
Biosimilar Names
Approval Dates
On Market
Biologic
Biosimilars
Patent
Antitrust
57%
MVASI
9/14/2017
Y
71%
Y
ZIRABEV
6/27/2019
Y
67%
Y
(settled)